Sequent Scientific Limited , a prominent player in the life sciences sector, has announced a significant corporate action that could reshape its identity. The company's board of directors has approved a proposal to change its name as part of a comprehensive merger scheme involving multiple entities.

Key Details of the Proposed Name Change

The board has given the green light to include the word 'Viyash' in the company's new name, subject to the effectiveness of a composite scheme of amalgamation. The proposed new names under consideration are:

• Viyash Scientific Limited
• Viyash Pharma Limited
• Viyash Healthcare Limited

This move aims to create a unified identity that reflects the combined strengths of the merged entities and leverages the brand equity of the Viyash group.

Merger Scheme Overview

The name change is part of a larger composite scheme of amalgamation that involves Sequent Scientific Limited and nine other companies. The key entities in this merger include:

1. Viyash Life Sciences Private Limited
2. Symed Labs Limited
3. Seven other entities (names not specified in the provided information)

Regulatory Approvals and Next Steps

The proposed name change is subject to several conditions:

1. Effectiveness of the merger scheme
2. Receipt of necessary statutory and regulatory approvals
3. Shareholder approval under the Companies Act, 2013
4. Approval from the Central Registration Centre, Ministry of Corporate Affairs

Implications and Outlook

This corporate action signifies a strategic move by Sequent Scientific to align its brand identity with the Viyash group, potentially indicating a shift in the company's market positioning and business focus. The merger and subsequent rebranding could lead to synergies among the involved entities, possibly enhancing the company's competitive position in the life sciences sector.

Investors and stakeholders should keep a close watch on further developments regarding the merger scheme and the final approval of the new name. These changes could have significant implications for the company's future operations and market perception.

As the situation evolves, more details are expected to emerge about the potential impact of this merger on Sequent Scientific's business operations, market strategy, and financial outlook.

Sequent Scientific , a prominent player in the life sciences sector, has initiated a postal ballot process to seek shareholder approval for the appointment of Mr. Anuj Poddar as a Non-Executive Director. This move comes as part of the company's efforts to strengthen its board with experienced professionals.

Key Details of the Appointment

• Mr. Anuj Poddar was initially appointed as an Additional Non-Executive Director on September 5, 2025.
• The company is now seeking shareholder approval to formalize his position as a Non-Executive Director.
• If approved, Mr. Poddar will serve as a nominee of The Carlyle Group on Sequent Scientific's board.

Voting Process

• The remote e-voting period will run from October 4 to November 2, 2025.
• Results of the postal ballot are expected to be announced by November 4, 2025.
• The cut-off date for voting eligibility is set at September 26, 2025.

About Anuj Poddar

Mr. Anuj Poddar brings a wealth of experience to Sequent Scientific:

• Currently serves as Managing Director and Asia Co-Head of Global Portfolio Solutions at Carlyle, a global investment firm managing $465.00 billion in assets.
• Previously held the position of Managing Director and CEO at Bajaj Electricals, where he drove significant transformation and value creation.
• Has over 13 years of experience with Viacom18 Media, playing a key role in the company's growth.
• Holds a rank in Chartered Accountancy and is an Aspen Fellow.

Board's Rationale

The Nomination and Remuneration Committee and the Board of Directors believe that Mr. Poddar's induction will bring valuable experience to Sequent Scientific, particularly in light of increasing business complexities and evolving regulatory landscapes.

Remuneration

It's noteworthy that Mr. Poddar will not receive any sitting fees or commission for his role. However, he will be entitled to reimbursement of expenses incurred on behalf of the company, in line with company policy.

Sequent Scientific's move to appoint Mr. Anuj Poddar reflects the company's commitment to enhancing its board's expertise and strategic capabilities. Shareholders will have the opportunity to vote on this appointment, potentially shaping the future direction of the company's governance and strategic initiatives.